Many parents tell kids about breast cancer gene test results
Parents are more likely than not to tell their sons and daughters younger than 25 years whether or not the parent carries inheritable mutations in BRCA1 or BRCA2 genes.
Parents are more likely than not to tell their sons and daughters younger than 25 years whether or not the parent carries inheritable mutations in BRCA1 or BRCA2 genes.
Mutations in the ATM gene may raise a person’s hereditary risk for pancreatic cancer, information that could lead to better screening methods for the disease.
A multigene test for predicting risk of breast cancer recurrence represents the first such assay used to differentiate lower-risk ductal carcinoma in situ from more aggressive forms.
Women with a variant of the KRAS oncogene are three times more resistant to platinum chemotherapy, the standard treatment for ovarian cancer, than are women without this variant.
Identifying the “mutational landscape” of a person’s cancer is a promising method of determining which trials are best-suited to the patient’s particular case.
Hematopoietic stem cells from healthy persons older than 65 years make fewer immunoprotective lymphocytes than do stem cells from healthy persons aged 20 to 35 years.
Genetic evaluations by a multidisciplinary health team improved risk prediction for children with retinoblastoma and their relatives, and prevented overuse of clinical screening tests.
The recent discovery of gene mutations in a genomic study of myelodysplastic syndromes could enable diagnosis using only a blood test rather than a bone marrow biopsy.
A vasodilator that blocks the activity of a protein called Rho kinase (ROCK) may be effective against difficult-to-treat types of leukemia.
A genetic defect found on the GATA2 gene predisposes people to acute myeloid leukemia (AML) and myelodysplasia, researchers have learned.